glp-1 food industry news today What to know about packaged foods aimed at users of weight-loss drugs From 'companion foods' to 'Nature's

Retatrutide is a new medication (still in development and not FDA-approved for treatment at this stage) that holds promise for helping people manage obesity and other related health issues

Erratum in: Nat Commun

Both the semaglutide and tirzepatide shortages that made compounding legally available were declared resolved in 2024 and 2025, the compounding wind-down deadlines have passed, and in April 2026 the FDA proposed closing the remaining legal pathway entirely

These options are prescribed only when appropriate and based on individual patient needs

By morning, the worst of the nausea has often passed

The gut microbiota influences skeletal muscle mass and function in mice